Comparison of Authentic and Suspect Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Comparison of Authentic and Suspect Pharmaceuticals
The authors applied near-infrared (NIR) spectrophotometry to assess whether eight drug products were authentic or counterfeit.


Pharmaceutical Technology
Volume 33, Issue 8, pp. 46-52


Table II: Near-infrared spectra comparisons of test product to reference product using ρm and δa.
Table II lists NIR spectra comparison results in terms of the ρm and δacriteria. Essentially, ρm is a ratio-based method, but δa is based on the absolute difference between two spectra (10, 11). Each method compares profiles at the same wavelength and can include all or selected wavelengths. If the profiles are identical, ρm = 0. Dissimilar profiles result in ρm that approaches infinity. This approach results in a ratio to assess spectra similarity, in which the larger value of either R t /T t or Tt/R t is considered at each wavelength. By virtue of being a ratio approach, ρm normalizes the differences between the profiles against the size of the profiles (i.e., it results in a value that quantifies the relative difference between the two profiles). δa also considers the relative size of the profiles. The authors used critical limits of ρm > 0.15 and δa > 15 to denote products that were not similar to their references because these limits represent a difference of more than 15% from the reference.


Figure 7. Near-infrared spectra of Norvasc 10 mg test and reference products and authentic generic amlodipine besylate 10 mg.
Spectra were compared over the 400–2500-nm range and over the 800–2500-nm range. Because 400–800 nm is the visible range and color differences (e.g., between dyes) are frequently and easily imparted to products designed for different countries, the narrower 800–2500-nm range was used to minimize colorant differences.


Figure 8. Near-infrared spectra of Viagra 50 mg test and reference products.
The results of ρm and δa generally followed the results of simple visual inspection of the tablets (see Table II). Most test spectra were similar to the reference spectra (i.e., ρm < 0.15 and δa < 15), and most products appeared to be authentic. Hence, the authors concluded that test Cialis 20 mg, test Lamisil 250 mg, test Levitra 20 mg, test Norvasc 5 mg, test Viagra 50 mg, and test Viagra 100 mg were authentic. TLC results from the terbinafine hydrochloride products and API indicated that test Lamisil 250 mg contained the labeled drug. TLC results from sildenafil citrate products and API indicated that test Viagra products contained the labeled drug.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here